New study tracks Nucala's Long-Term impact on rare inflammatory disease
NCT ID NCT03557060
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study followed about 300 people with EGPA (a rare disease causing inflammation in blood vessels) who were treated with Nucala injections for up to 2 years. Researchers monitored side effects, how well the drug controlled symptoms, and how long it took for the disease to flare up again. The goal was to see if Nucala remains safe and effective when used long-term in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nucala (mepolizumab)
- What this could lead to
- If successful, this could confirm that long-term Nucala is a safe and effective way to control EGPA and prevent relapses.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. Side effects are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHURG-STRAUSS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Tokyo, 107-0052, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hydroxychloroquine trial for rare vasculitis halted early
- New hope for rare disease: can NS-229 help patients reduce steroids?
- Scientists build tissue bank to unlock vasculitis mysteries
- Scientists hunt for clues to rare immune disease
- New drug aims to tame rare inflammatory disease EGPA
- New drug MT-2990 tested in rare blood vessel disease